Recently, while preparing an updated presentation to the Saint Louis University cardiology fellows on "diastolic dysfunction," the Skeptical Cardiologist came across a document entitled "What Does ...

Please provide your email address to receive an email when new articles are posted on . An AI algorithm for detection of grade 3 diastolic dysfunction received a breakthrough device designation from ...

Diastolic dysfunction increasingly is recognized as an important cause of congestive heart failure (CHF). In this study, Mayo Clinic researchers surveyed a random sample of 2042 adults (age, 45 or ...

While cardiovascular disease (CVD) is more common in young men than in young women, the risk of CVD increases for postmenopausal women, making them nearly as susceptible as men. Menopause typically ...

Researchers from Edgewise Therapeutics Inc. presented preclinical data for the cardiac sarcomere modulator, EDG-7500, which is being developed for the treatment of hypertrophic cardiomyopathy (HCM) ...

Please provide your email address to receive an email when new articles are posted on . Diastolic dysfunction is an independent risk factor for increased mortality risk among patients with systemic ...

Objective The left atrial stiffness index (LASI) has been proven to be a promising marker for assessing left atrial (LA) and ...

Sudden cardiac death is a common cause of death in patients with reduced systolic ejection function. As part of a long-term observational study, MedUni Vienna researchers from the Division of ...

Echocardiographic data analysis demonstrated favorable impact of atrioventricular interval modulation (“AVIM”) therapy on MODERATO II study patients with diastolic dysfunction, a key component in the ...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced initial dosing in a Phase 1 trial of EDG-7500.